News
The U.S. FDA has paused Rocket Pharmaceuticals' mid-stage gene therapy trial after a patient died from serious complications, ...
Pioneering gene editing therapy could give 5-year-old with rare, fatal disorder a new chance at life
A 5-year-old boy from Center City has faced rare odds since birth and now this warrior is in a real life race to rewrite his story.
The FDA has slapped a clinical hold on Rocket Pharmaceuticals’ pivotal gene therapy trial in response to a death. Rocket, ...
In comments posted in response to the Trump administration’s pharma tariff investigation, companies and industry groups ...
FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...
Acute systemic infection caused the patient to develop fatal capillary leak syndrome, highlighting the unpredictability of ...
Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...
7d
Clinical Trials Arena on MSNPatient dies in Rocket’s Phase II Danon disease gene therapy trialThe FDA ordered a clinical hold on Rocket Pharmaceuticals' Danon disease trial after the adverse event was first disclosed.
The personalized CRISPR treatment could be the future of gene therapy, but hurdles remain before everyone has access.
Rocket Pharmaceuticals shares plummeted 60% Tuesday after the firm said it halted a study of a gene-therapy drug for Danon ...
While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...
The U.S. FDA has paused a mid-stage gene therapy trial by Rocket Pharmaceuticals after a patient suffered serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results